Baxter Splits into Two

Mar 27, 2014

Baxter International

Baxter International announced plans to create two separate, independent healthcare companies - one focused on developing and marketing biopharmaceuticals and the other on medical products.

The medical products business, which will keep the Baxter name, includes a portfolio of intravenous and nutritional therapies, drug delivery systems and administration sets, premixed and other injectable drugs, as well as inhalation anesthetics and hospital-based biosurgery products.

The new biopharmaceuticals company, which offers treatments for hemophilia, bleeding disorders, immune deficiencies, and chronic and acute blood-related conditions, has yet to be named.

The split is expected to be completed by mid-year 2015, subject to market, regulatory and other conditions.

Read the Baxter press release


Join the discussion

We welcome your thoughtful comments. Please comply with our Community rules.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments